CNR2 and irritable bowel syndrome: This review focuses on the role of type 1 and type 2 cannabinoid receptors and novel components of the so-called endocannabinoidome in IBD, describing their physiological and molecular functions and the adequacy of cannabinoid-based therapies in chronic IBD.